Jennifer Wu
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Prostate cancer is a heterogeneous disease with a spectrum of pathology and outcomes ranging from indolent to lethal. Although there have been recent advancements in prognostic tissue biomarkers, limitations still exist. We leveraged matrix-assisted laser desorption/ionization imaging of formalin-fixed, paraffin embedded prostate cancer specimens to determine if N-linked glycans expressed in the extracellular matrix of lethal neuroendocrine prostate cancer were also expressed in conventional prostate adenocarcinomas that were associated with poor outcomes. We found that N-glycan fucosylation was abundant in neuroendocrine prostate cancer as well as adenocarcinomas at the time of prostatectomy that eventually developed recurrent metastatic disease. Analysis of patient-derived xenografts revealed that this fucosylation signature was enriched differently across metastatic disease organ sites, with the highest abundance in liver metastases. These data suggest that N-linked fucosylated glycans could be an early tissue biomarker for poor prostate cancer outcomes. Implications: These studies identify that hyper-fucosylated N-linked glycans are enriched in neuroendocrine prostate cancer and conventional prostate adenocarcinomas that progress to metastatic disease, thus advancing biomarker discovery and providing insights into mechanisms underlying metastatic disease.
Year:
2025
Background/Objectives: Soft tissue sarcomas (STS) remain a therapeutic challenge due to their limited response to radiation and conventional chemotherapies. While recent advances in immunotherapy have improved outcomes in several cancers, these strategies have been largely disappointing in STS patients. Naturally occurring STS in dogs have been suggested as a spontaneous, immunocompetent model of human STS, but further characterization of its tumor immune microenvironment is needed to validate its relevance. This study aimed to identify the shared immune-related components of canine and human STS and to determine how these factors influence the tumor biology, progression, and prognosis. Results: Data from 75 dogs with STS was analyzed. In addition, we characterized the tumor immune microenvironment using immunohistochemistry and compared gene expression between canine and human STS. Progression-free survival and time to metastasis was significantly longer in castrated males in comparison to females. In addition, dogs with appendicular tumors had better progression- and recurrence-free survival, whereas tumor recurrence following surgical excision was associated with a shorter time to metastasis. Immunohistochemistry revealed infiltration of CD204+ cells in most of the tumors examined, and disease-free intervals were shorter in dogs with tumors exhibiting FOXP3+ cell infiltration. Gene expression profiling demonstrated similarities between canine STS and human undifferentiated pleomorphic sarcomas, with MYC dysregulation emerging as a poor prognostic indicator for dogs. Conclusions: The comparative analysis between the human and canine STS microenvironment offers a valuable insight into the clinical behavior and immune landscape of canine STS, underscoring its potential as a relevant preclinical model for the translation and development of future immunotherapies.
Year:
2025
Year:
2025
Prostate cancer is a heterogeneous disease with a spectrum of pathology and outcomes ranging from indolent to lethal. Although there have been recent advancements in prognostic tissue biomarkers, limitations still exist. We leveraged matrix-assisted laser desorption/ionization imaging of formalin-fixed, paraffin embedded prostate cancer specimens to determine if N-linked glycans expressed in the extracellular matrix of lethal neuroendocrine prostate cancer were also expressed in conventional prostate adenocarcinomas that were associated with poor outcomes. We found that N-glycan fucosylation was abundant in neuroendocrine prostate cancer as well as adenocarcinomas at the time of prostatectomy that eventually developed recurrent metastatic disease. Analysis of patient-derived xenografts revealed that this fucosylation signature was enriched differently across metastatic disease organ sites, with the highest abundance in liver metastases. These data suggest that N-linked fucosylated glycans could be an early tissue biomarker for poor prostate cancer outcomes. Implications : These studies identify that hyper-fucosylated N-linked glycans are enriched in neuroendocrine prostate cancer and conventional prostate adenocarcinomas that progress to metastatic disease, thus advancing biomarker discovery and providing insights into mechanisms underlying metastatic disease.
Year:
2025
Statistical analysis of detected N-glycans in each category of TMA. A, PCA score plot of all 152 N-glycans. B, PLS-DA plot and corresponding importance feature plot. C, t test plot of NED vs. MET with structures shown for the top 10 most significant peaks. D, Pattern search graph showing the top 25 peaks correlated with 2905.0368 (Hex8dHex1HexNAc7), m / z values of N-glycans with at least one or more fucose shown in red boxes. VIP, variable importance in projection.
Year:
2025
Analysis of collagen/ECM profile of NED vs. MET cohort from data obtained by LC-MS/MS. A, Pie chart representations of abundance (peak intensity and number of peptides identified via LC-MS/MS) of all detected protein species within the MET cohort. B, Pie chart representations of abundance of all detected protein species within the NED cohort.
Year:
2025
Statistical analysis of detected N-glycans in each category of TMA following EndoF3 and PNGaseF digestion. A, t test plot of detected N-glycans following EndoF3 digestion. Structures shown for top 10 most significant N-glycans ( B ) t test plot of detected N-glycans following PNGaseF digestion. Structures shown for top 10 most significant N-glycans C, Left-Right: PCA, PLS-DA plots for detected N-glycans following EndoF3 digestion. ROC curve showing NED vs. MET after EndoF3 digestion D, Left-Right: PCA, PLS-DA plots for detected N-glycans following PNGaseF digestion. ROC curve showing NED vs. Mets after PNGaseF digestion.
Year:
2025
Prostate cancer is a significant health concern, with metastasis posing major clinical challenges and resulting in poor patient outcome. Despite screening and treatment advances, a critical need for novel biomarkers to predict prostate cancer progression at the time of prostatectomy persists. Here, we assessed aberrant N-glycosylation patterns and alterations in extracellular matrix (ECM) proteins as potential biomarkers of predicting prostate cancer severity in a unique patient outcome cohort. Tissue microarray slides were assembled from primary prostatectomy specimens that were categorized into “no evidence of disease (NED)” and “metastasis (MET)” designations based on >5-year disease progression outcomes. Serial mass spectrometry imaging techniques were performed to analyze N-glycans and ECM components in formalin-fixed paraffin-embedded cores. The results revealed a significant upregulation of bisecting and multiantennary core-fucosylated N-glycans in MET tissues when compared with NED tissues. Alterations in ECM composition in both NED and MET cohorts were observed, particularly in collagen species and the amount of hydroxyproline content. Results suggest a coordinated alteration of ECM protein and glycosylation content in prostate cancer tissues can be predictive for postprostatectomy disease progression. Significance: Using matrix-assisted laser desorption/ionization mass spectrometry imaging techniques on a unique cohort of prostate cancer tissues, we highlighted several molecular characteristics of matrix that have potential to act as early predictors of prostate cancer metastasis.
Year:
2025
Purpose: Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a median age of onset of 68 to 70 years old. Although advanced age is often associated with poorer GBM patient survival, the predominant source(s) of maladaptive aging effects remains to be established. Here, we studied intratumoral and extratumoral relationships between adult patients with GBM and mice with brain tumors across the lifespan. Experimental Design: Electronic health records at Northwestern Medicine and the NCI SEER databases were evaluated for GBM patient age and overall survival. The commercial Tempus and Caris databases, as well as The Cancer Genome Atlas were profiled for gene expression, DNA methylation, and mutational changes with varying GBM patient age. In addition, gene expression analysis was performed on the extratumoral brain of younger and older adult mice with or without a brain tumor. The survival of young and old wild-type or transgenic (INK-ATTAC) mice with a brain tumor was evaluated after treatment with or without senolytics and/or immunotherapy. Results: Human patients with GBM ≥65 years of age had a significantly decreased survival compared with their younger counterparts. While the intra-GBM molecular profiles were similar between younger and older patients with GBM, non-tumor brain tissue had a significantly different gene expression profile between young and old mice with a brain tumor and the eradication of senescent cells improved immunotherapy-dependent survival of old but not young mice. Conclusions: This work suggests a potential benefit for combining senolytics with immunotherapy in older patients with GBM.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (28)
Olivier Elemento
Professor
Weill Cornell Medical College
Craig Horbinski
Northwestern University
Rimas V Lukas
Northwestern University
Ping Xie
Research Assistant Professor
Northwestern University
Seth M. Pollack
University of Washington
Nikolaos Trikalinos
Assistant Professor
Washington University in St. Louis
Soma Sengupta
Chair
Tufts Medical Center
Xinlei Mi
Assistant Professor
Northwestern University Feinberg School of Medicine
Shay Bracha
Associate Professor
Ohio State University
Dongjun Chung
Professor
Ohio State University
Prashant Vikram Bommi
Asst. Professor - Research
Loyola University Chicago
Eva Corey
Professor
University of Washington
Theresa Walunas
Associate Professor
Northwestern University Feinberg School of Medicine
Hyunsoo Cho
Clinical Assistant Professor
Seoul National University Hospital
Margaret O Johnson
Duke University School of Medicine
Robin Leach
Professor
-
Lyndsay Young
Research Assistant Professor
Medical University of South Carolina
Deyali Chatterjee
Associate Professor
Vanderbilt University Medical Center
Jonathan Gelfond
Professor
University of Texas Health Science Center at San Antonio
Anand S. Mehta
SmartState Endowed Chair of Proteomic Biomarkers and Professor
Medical University of South Carolina
Joseph E Ippolito
Associate Professor
Washington University School of Medicine
Lauren Ball
Director, Mass Spectrometry Facility; Associate Professor
Medical University of South Carolina
Derek Wainwright
Associate Professor, Scientific Director for Brain Tumor Research
Loyola University Chicago Stritch School of Medicine
Eric Kim
Associate Professor of Surgery
Washington University in Saint Louis School of Medicine
Regina Hayburn
Clinical Assistant Professor of Medical Oncology
Texas A&M University
Gary E. Schiltz
Northwestern University
Richard Drake
Professor and Endowed Chair in Proteomics
Medical University of South Carolina
Darren Baker
Professor
Mayo Clinic
Make your next move.
Prepare your application
Review drafts before you send them.